Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer
22:31 EDT 9 Jul 2018 |
SCRIP
Astellas and Seattle Genetics now expect key top-line data on their antibody-drug conjugate in urothelial cancer in the first half...
More From BioPortfolio on "Enfortumab Progresses As US Accelerated Approval Eyed In Urothelial Cancer"